Research at the Diabetes Trials Unit is set to benefit from renewed funding of the Oxford Biomedical Research Centre (OxBRC) by the National Institute for Health Research (NIHR). The OxBRC was recently awarded £95m, an increase of 50% on the previous allocation, to support translational research.
The OxBRC was one of five centres funded by the National Institute of Health Research in 2007 through a competitively awarded grant of £57m over five years. As part of the Government's initiative to improve the translation research, the OxBRC is a partnership that brings together the research expertise of the University of Oxford and the clinical skills of staff of Oxford Radcliffe Hospitals NHS Trust.
On the announcement, Professor Ted Baker, Medical Director of the Oxford Radcliffe Hospitals NHS Trust, said: 'The research collaboration between Oxford Radcliffe Hospitals and the University, through the NIHR Biomedical Research Centre, underpins and drives forward improvements in patient care by bringing innovation from the laboratory bench to the patients' bedside. This new award will help the Trust continue developing new ways of caring for patients by providing an environment where clinicians and scientists can flourish.'
The funding allocated to the Diabetes Trials Unit will be channelled into the work of the Translational Research Group (TRG), driving innovative methods for the prevention, diagnosis and treatment of diabetes. You can find out more about the work of the TRG on their web pages.